Skip to content
    Adage Capital Management logo

    Adage Capital Management

    Boston, Massachusetts, United StatesFounded 2001
    www.adagecapital.comLinkedIn
    HealthcareBiotech & Life Sciences

    Adage Capital Management is a Boston-based investment management firm founded in 2001 that primarily manages S&P 500 equity portfolios for endowment and foundation clients using fundamental analysis. The firm also makes selective private equity investments in startups and early-stage companies, particularly in healthcare and life sciences.

    41% of their portfolio is in Biotech & Life Sciences. Deal activity increased 400% year-over-year (5 deals in the last 12 months). Average disclosed round size is $133.9M (across 87 rounds with reported amounts).

    Find people at Adage Capital Management on Goldilocks AI

    Portfolio

    72

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    5

    Team

    BA

    Bob Atchinson

    Managing Director

    PG

    Phill Gross

    Managing Director

    RA

    Robert Atchinson

    Managing Director

    RS

    Richard Solit MD

    Partner

    SA

    Scott A. Wilson

    Analyst (TMT/Software)

    YP

    Yang Pu, CFA

    Analyst

    JC

    Jeffrey Cho, CFA

    Portfolio Manager

    PS

    Prachi Samudra

    Portfolio Manager

    RN

    Robert Neukomm

    Portfolio Manager

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    94 investments
    CompanyRoundAmountDate
    Ovid Therapeutics Inc. logoOvid Therapeutics Inc.Unknown$60MMar 2026
    CCorxel Pharmaceuticals LimitedSeries D$287MJan 2026
    CClaris BioSeries B$57MJan 2026
    Artiva Biotherapeutics logoArtiva BiotherapeuticsSeries B$120MJan 2026
    OnKure Therapeutics logoOnKure TherapeuticsSeries C$150MJan 2026
    Claris logoClarisSeries B$118MJan 2026
    Ambros Therapeutics logoAmbros TherapeuticsSeries A$125MDec 2025
    KKaileraSeries B$600MOct 2025
    PsiQuantum logoPsiQuantumSeries E$1BSep 2025
    DDBV Technologies S.A.Unknown$306.9MMar 2025
    PsiQuantum logoPsiQuantumSeries E$1BJan 2025
    Mirador logoMiradorSeries B$250MJan 2025
    Ambros Therapeutics logoAmbros TherapeuticsSeries A$125MJan 2025
    Claris logoClarisSeries A$57MJan 2024
    Gracell Biotechnologies logoGracell BiotechnologiesGrowth$150MAug 2023
    HawkEye 360 logoHawkEye 360Series D$58MJul 2023
    Harness logoHarnessSeries D$230MApr 2022
    HHarness.ioSeries D$230MApr 2022
    MMenlo MicrosystemsSeries C$150MMar 2022
    Menlo Micro logoMenlo MicroSeries C$150MMar 2022
    HawkEye 360 logoHawkEye 360Series D$145MNov 2021
    HHawkeyeSeries D$145MNov 2021
    Beckley Psytech logoBeckley PsytechSeries B—Aug 2021
    GOAT Group logoGOAT GroupSeries F$195MJun 2021
    GOAT logoGOATSeries E$100MJun 2021
    Page 1 of 4

    Top Co-Investors

    RA Capital Management25 shared
    T. Rowe Price12 shared
    Sofinnova Partners10 shared
    New Enterprise Associates9 shared
    Logos Capital9 shared
    Surveyor Capital9 shared
    The Invus Group, LLC9 shared
    HBM Healthcare Investments9 shared
    Balyasny Asset Management8 shared
    OrbiMed8 shared
    Bain Capital Life Sciences8 shared
    Novo Capital8 shared
    Franklin Templeton7 shared
    RiverVest Venture Partners7 shared
    BlackRock Private Equity Partners7 shared
    Cormorant Asset Management7 shared
    Rock Springs Capital7 shared
    Morgenthaler Ventures7 shared
    Pappas Capital6 shared
    Redmile Group6 shared

    Last updated: 7 October 2026